Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
about
Complement in Lupus Nephritis: New PerspectivesLupus nephritis: the evolving role of novel therapeuticsA prototype pathogen bound ex vivo to human erythrocyte complement receptor 1 via bispecific monoclonal antibody complexes is cleared to the liver in a mouse model.Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage.CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis.Molecules Great and Small: The Complement System.Review: Complement and its regulatory proteins in kidney diseases.Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) diseaseTargeting of functional antibody-CD59 fusion proteins to a cell surface.The role of neutrophils and NETosis in autoimmune and renal diseases.Naja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr MiceMonoclonal antibodies and other biologic therapies.Pathogenesis of systemic lupus erythematosus (SLE).New therapies in development for autoimmune diseases: their rationale for combination treatment.Novel approaches in the treatment of lupus nephritis.Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient miceNovel therapeutic agents in clinical development for systemic lupus erythematosus.Therapy of systemic lupus erythematosus: a look into the futureComplement and systemic lupus erythematosus.The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.Role for complement in development of Helicobacter-induced gastritis in interleukin-10-deficient mice.Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation.Immunotherapy for autoimmune and inflammatory renal diseases.Complement involvement in kidney diseases: From physiopathology to therapeutical targetingInhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus.A simple PCR-based method for the rapid genotyping of inherited fifth complement component (C5)-deficient mice.Pathogenic autoantibodies in lupus nephritis.Novel therapies in lupus nephritis.Theory, targets and therapy in systemic lupus erythematosus.Pathogenesis of lupus nephritis: an update.Complement and its breakdown products in SLE.Metabolic regulation of organelle homeostasis in lupus T cellsNovel C5a regulators in inflammatory disease.Noninvasive Imaging of Activated Complement in Ischemia-Reperfusion Injury Post-Cardiac TransplantPreeclampsia: the death of Goliath.Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon gamma: a possible initiating role of B cells.Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injuryAbsence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice.Complement deficiencies in humans and animals: links to autoimmunity.The role of complement in autoimmune renal disease.
P2860
Q26740491-35F8437E-2E5F-4A3D-8648-0D56ED45AB37Q26998390-40F561FF-423D-449F-8930-92D6EF72692AQ30304046-1597058E-93C4-4583-BA27-B4DCA6FC118CQ30433903-A3029A1A-6AB9-4966-B8B1-06F5D11866D8Q30453105-ACBEB44E-5963-4CE4-AE2B-ACD3B2575122Q33419651-E185CC79-9012-4314-B2A2-BEA075B57019Q33647738-FAE7FD88-B071-4E1C-8AD4-C47A82E4068AQ33769083-B854E1E6-DFD9-4570-8ADB-F23DE60C5C14Q33834216-871C2F9A-5B15-42D1-BE2D-63D2456D9DCCQ33904653-B4E21FF0-49DD-49BD-8DBE-94BB0CF0E067Q33908254-47AA646C-2FB4-47B7-B710-BEFCE6ABFA57Q34227074-FFA93329-BCCE-4E02-B8CD-14FF23321C0CQ34291300-0A8397E7-DE32-40CF-A773-BC63B58FF8CFQ34309745-F3132D5B-4DBB-4BD4-BDB2-A90BA88EC4A1Q34481499-60D2349B-DFF6-4EC5-840F-C8EE1DA556EFQ34537391-2F3A7DB4-CDB4-4013-BA32-AB0C133B7AB0Q34704902-B855300B-5644-4289-8F1F-4186A9EFCFCFQ34731092-530171EF-2A11-44A2-A476-9209C93D93C6Q34731255-1560DB02-3232-4E86-9D73-57096B67F631Q34813568-8C3D0C14-E395-46D9-B527-E7DB90413674Q34940884-3D963207-93CF-40C3-8AF4-10F2E08DFD1BQ35095565-D45721A6-DF02-4263-8447-3660629C3383Q35144046-BAA9EAFD-4805-4060-ABC1-54A3B6E19705Q35567841-39A83E0E-751D-4B1E-8D85-F5E681794A3CQ35824482-995B1321-D14A-4B68-9142-A702CA73C6CEQ35991991-A7D0BC0D-D96D-4791-B79A-1D6CCEB492B0Q36054822-DA2CDD32-CB55-4901-9EE7-6BFB8A0DAC22Q36054877-33D39B38-0164-46B8-9307-51D979D5ABA8Q36088035-3E817654-B3BB-4363-9BF6-70F54FFA30F0Q36118530-31AB05BE-2BD8-4C05-AEA9-4D7846F6F119Q36171508-F935E5E9-DDD0-42BF-9E30-AD36275FADEFQ36177195-59366557-0E47-45F9-8685-1DFFB809422BQ36196446-2F63E805-4DD4-4A57-8908-1AD97B2FAC73Q36302489-CD8B5A47-71AC-4AAC-BFDD-36A02190CE77Q36376515-30168F35-68B3-4221-AEC3-A65644A9BCC4Q36380633-FD7B2D97-92AB-49CF-886F-4010F77CCE60Q36401591-84BDDA2E-7B57-473B-9018-D6854F15D5A8Q36426921-4F6E5BE8-02F5-4B25-ACD7-840EA45C5B77Q36572977-0242E7AD-4E98-4980-987D-A49C6346416CQ36573001-573F62AA-3A37-4988-BCD3-1C0BF28A465F
P2860
Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Amelioration of lupus-like aut ...... c for complement component C5.
@en
Amelioration of lupus-like aut ...... c for complement component C5.
@nl
type
label
Amelioration of lupus-like aut ...... c for complement component C5.
@en
Amelioration of lupus-like aut ...... c for complement component C5.
@nl
prefLabel
Amelioration of lupus-like aut ...... c for complement component C5.
@en
Amelioration of lupus-like aut ...... c for complement component C5.
@nl
P2093
P2860
P356
P1476
Amelioration of lupus-like aut ...... c for complement component C5.
@en
P2093
P2860
P304
P356
10.1073/PNAS.93.16.8563
P407
P577
1996-08-01T00:00:00Z